On August 18, 2026, the U.S. Food and Drug Administration (FDA) published a discussion paper seeking stakeholder feedback on potential approaches to generative artificial intelligence (GenAI)-enabled medical devices. The agency explored risk assessment, premarket evaluation, postmarket monitoring, and considerations involving foundation models and agentic AI. The discussion is important for manufacturers because GenAI outputs can vary with prompts, context, model versions, and operating conditions.

Crucially, this publication is a discussion paper—not draft guidance, final guidance, a new regulation, or a statement of current FDA evidentiary expectations. Companies should distinguish exploratory concepts from existing device requirements while preparing quality systems to manage emerging technical risks.